AUG 28, 2018 09:58 PM PDT

Combination Therapy for Advanced Melonoma

WRITTEN BY: Nouran Amin

Image: Cancer Research UK

According to a research study led by UCLA, a bacteria-like agent used in combination with an immunotherapeutic drug may help patients survive longer with advanced melanoma; an aggressive skin cancer. The research examined the molecular actions of an immunotherapy drug pembrolizumab and the bacterial agent SD-101 (a pattern of nucleic acids imitating a bacterial infection) on their alteration of microenvironment enclosing a tumor. The alteration enabled the immune system to effectively increase its attack on cancer.

The immunotherapeutic drug, pembrolizumab, marketed under the brand name ‘Keytruda’, worked by inhibiting PD-1, which is a protein that exerts actions on the function of the immune system. Inhibiting PD-1 with pembrolizumab allowed the immune system cells to better recognize cancer. While Pembrolizumab is actually known for treating people with advanced or metastatic cancers, however, the majority of metastatic melanoma tumors resisted the effects of the drug. "We have found that the reason patients with metastatic melanoma do not initially respond to immunotherapy with an anti-PD-1 is that their immune system was not ready," explained Dr. Antoni Ribas, lead author, professor of medicine at UCLA’s David Geffen School of Medicine, and director UCLA Jonsson Comprehensive Cancer Center Tumor Immunology Program. "So we thought, 'What if we change that by injecting the therapeutic drug into the metastatic lesions and change the microenvironment of the cancer? It's like having a pile of wood but not having a match to light it. With this new approach, SD-101 is the match that starts the fire."

Image: NorthShore.org

Interestingly, scientists discovered that SD-101 not only orchestrates T cells to cancer cells but also ensures the microenvironment is appropriate for T cells; allowing them to eradicate cancer cells. "For all patients with advanced cancer, immunotherapy using PD-1 inhibitors has really changed the face of cancer treatment. Unfortunately, this therapy still only works in a subset of patients," says Dr. Deborah Wong, author of the study and oncologist at the Ronald Reagan UCLA Medical Center. "This particular combination has been especially gratifying because not only does the SD-101 therapy drug induce tumor shrinkage at the actual site where it's injected, but it's working in conjunction with pembrolizumab to shrink tumors outside of the ones we're directly injecting."

The following study highlights the urge for more research behind combination therapies especially since many cancer patients do not readily respond to immunotherapy and often experience a reoccurrence of tumors post-treatment.

"We are really starting to understand the science of how immunotherapies work in patients," explained Ribas. “By understanding that, we can find more ways to make that therapy more active. One way is by combining the therapy with another agent that can overcome the resistance that some cancers have to these therapies."

Watch the video below to learn more about Melanoma!

Source: University of California - Los Angeles Health Sciences, Cancer Discovery

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 21, 2019
Cancer
SEP 21, 2019
Using VR to Design Medicine
Being able to visualize and precisely understand molecular shapes is a key factor in drug design. Over the years, to envision and better understand molecul...
SEP 21, 2019
Cell & Molecular Biology
SEP 21, 2019
Scratching a Chronic Itch
There are many potential reasons why skin might itch, but this annoying condition can significantly impact quality of life when it doesn't go away....
SEP 21, 2019
Chemistry & Physics
SEP 21, 2019
Chemists Synthesized Effective Antidote For Uranium Poisoning
Uranium poisoning is unusual to the general population but does happen to miners, mineral mill and fabrication workers. Through inhaling and ingestion, ura...
SEP 21, 2019
Technology
SEP 21, 2019
How Bitcoins Can Advance Medication Usage
Will futuristic concepts from the world of technology likely find a place in our medicine cabinet? Maybe! The new concept has been known as ‘cryptoph...
SEP 21, 2019
Drug Discovery & Development
SEP 21, 2019
Unprecedented Therapeutic Found Effective for Blood Cancer
According to the findings of a clinical trial, scientists at Mt. Sinai have found a new therapeutic effective for patients with a particular type of b...
SEP 21, 2019
Drug Discovery & Development
SEP 21, 2019
Does TruBrain Really Work?
TruBrain is a mix of different substances claimed to help people increase verbal fluency, avoid distractions, and boost their mental output. Created by a t...
Loading Comments...